CN101189251B - 17β-HSD1和STS抑制剂 - Google Patents
17β-HSD1和STS抑制剂 Download PDFInfo
- Publication number
- CN101189251B CN101189251B CN2006800183025A CN200680018302A CN101189251B CN 101189251 B CN101189251 B CN 101189251B CN 2006800183025 A CN2006800183025 A CN 2006800183025A CN 200680018302 A CN200680018302 A CN 200680018302A CN 101189251 B CN101189251 B CN 101189251B
- Authority
- CN
- China
- Prior art keywords
- alkyl
- female
- triolefins
- group
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CC(*)(C1C****)C(*)(*)[C@@](C)(CC2)[C@@]1[C@@](CCc1c3)[C@]2c1cc(*)c3O* Chemical compound CC(*)(C1C****)C(*)(*)[C@@](C)(CC2)[C@@]1[C@@](CCc1c3)[C@]2c1cc(*)c3O* 0.000 description 19
- NIJVOHDAEVGIAI-OSKKXLQOSA-N C[C@@]1(CC2)C(C(F)(F)F)=C[C@@H](CCCC(N3CCOCC3)=O)[C@H]1[C@H](CCc1c3)[C@H]2c1ccc3O Chemical compound C[C@@]1(CC2)C(C(F)(F)F)=C[C@@H](CCCC(N3CCOCC3)=O)[C@H]1[C@H](CCc1c3)[C@H]2c1ccc3O NIJVOHDAEVGIAI-OSKKXLQOSA-N 0.000 description 1
- NLCBKTZKOVBSRE-KTGNPEENSA-N C[C@@]1(CC2)c3n[n](C)cc3[C@@H](CCCC(NCc3ccccc3)=O)[C@H]1[C@H](CC1)[C@H]2c(cc2)c1cc2O Chemical compound C[C@@]1(CC2)c3n[n](C)cc3[C@@H](CCCC(NCc3ccccc3)=O)[C@H]1[C@H](CC1)[C@H]2c(cc2)c1cc2O NLCBKTZKOVBSRE-KTGNPEENSA-N 0.000 description 1
- SCRNPEDEBGMDDD-IJPITKTISA-N C[C@](CC1)([C@@H](C(CCCC(O)=O)C2)[C@H](CCc3c4)[C@H]1c3ccc4O)C2=O Chemical compound C[C@](CC1)([C@@H](C(CCCC(O)=O)C2)[C@H](CCc3c4)[C@H]1c3ccc4O)C2=O SCRNPEDEBGMDDD-IJPITKTISA-N 0.000 description 1
- WVDSELMGBQZGHS-KTGNPEENSA-N C[C@](CC1)([C@@H]([C@@H]2CCCC(NCc3ccccc3)=O)[C@H](CCc3c4)[C@H]1c3ccc4O)c1c2cn[n]1C Chemical compound C[C@](CC1)([C@@H]([C@@H]2CCCC(NCc3ccccc3)=O)[C@H](CCc3c4)[C@H]1c3ccc4O)c1c2cn[n]1C WVDSELMGBQZGHS-KTGNPEENSA-N 0.000 description 1
- TZURBUPZHKQKBZ-LNNOLSETSA-N C[C@](CC1)([C@@H]([C@H](CCC(O)=O)C2)[C@H](CCc3c4)[C@H]1c3ccc4O)C2(F)F Chemical compound C[C@](CC1)([C@@H]([C@H](CCC(O)=O)C2)[C@H](CCc3c4)[C@H]1c3ccc4O)C2(F)F TZURBUPZHKQKBZ-LNNOLSETSA-N 0.000 description 1
- NDEWZPHRETZILE-TVNKATRISA-N C[C@](CC1)([C@@H]([C@H](CCCC(N2CCOCC2)=O)C2)[C@H](CCc3c4)[C@H]1c3ccc4O)C2=C(F)F Chemical compound C[C@](CC1)([C@@H]([C@H](CCCC(N2CCOCC2)=O)C2)[C@H](CCc3c4)[C@H]1c3ccc4O)C2=C(F)F NDEWZPHRETZILE-TVNKATRISA-N 0.000 description 1
- NUJZCCVHQHUDEQ-XBJFUPPCSA-N C[C@](CC1)([C@@H]([C@H](CCCC(O)=O)C2)[C@H](CCc3c4)[C@H]1c3cc(CCOC)c4O)C2=O Chemical compound C[C@](CC1)([C@@H]([C@H](CCCC(O)=O)C2)[C@H](CCc3c4)[C@H]1c3cc(CCOC)c4O)C2=O NUJZCCVHQHUDEQ-XBJFUPPCSA-N 0.000 description 1
- VQTVFIMEENGCJA-UHFFFAOYSA-N Cc1c(C)[nH]nc1 Chemical compound Cc1c(C)[nH]nc1 VQTVFIMEENGCJA-UHFFFAOYSA-N 0.000 description 1
- BSWGZCMLNFBDEZ-UHFFFAOYSA-N Cc1c(C)[o]nc1 Chemical compound Cc1c(C)[o]nc1 BSWGZCMLNFBDEZ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0036—Nitrogen-containing hetero ring
- C07J71/0042—Nitrogen only
- C07J71/0052—Nitrogen only at position 16(17)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0072—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the A ring of the steroid being aromatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0036—Nitrogen-containing hetero ring
- C07J71/0057—Nitrogen and oxygen
- C07J71/0068—Nitrogen and oxygen at position 16(17)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Reproductive Health (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05104534 | 2005-05-26 | ||
| EP05104534.2 | 2005-05-26 | ||
| PCT/EP2006/062587 WO2006125800A1 (en) | 2005-05-26 | 2006-05-24 | 17β-HSD1 AND STS INHIBITORS |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012103102224A Division CN102796160A (zh) | 2005-05-26 | 2006-05-24 | 17β-HSD1和STS抑制剂 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101189251A CN101189251A (zh) | 2008-05-28 |
| CN101189251B true CN101189251B (zh) | 2012-09-12 |
Family
ID=35276406
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2006800183025A Expired - Fee Related CN101189251B (zh) | 2005-05-26 | 2006-05-24 | 17β-HSD1和STS抑制剂 |
| CN2012103102224A Pending CN102796160A (zh) | 2005-05-26 | 2006-05-24 | 17β-HSD1和STS抑制剂 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012103102224A Pending CN102796160A (zh) | 2005-05-26 | 2006-05-24 | 17β-HSD1和STS抑制剂 |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP1888615B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5268635B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR101364412B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN101189251B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2006251154B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0611623A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2609726C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2388297T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL187620A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2007014736A (cg-RX-API-DMAC7.html) |
| NO (1) | NO20076616L (cg-RX-API-DMAC7.html) |
| RU (1) | RU2412196C2 (cg-RX-API-DMAC7.html) |
| UA (1) | UA92348C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2006125800A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA200709854B (cg-RX-API-DMAC7.html) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8080540B2 (en) | 2006-09-19 | 2011-12-20 | Abbott Products Gmbh | Therapeutically active triazoles and their use |
| AU2007327653B2 (en) * | 2006-11-30 | 2013-04-18 | Solvay Pharmaceuticals Gmbh | Substituted estratrien derivatives as 17beta HSD inhibitors |
| US8288367B2 (en) | 2006-11-30 | 2012-10-16 | Solvay Pharmaceuticals Gmbh | Substituted estratriene derivatives as 17BETA HSD inhibitors |
| US11072632B2 (en) | 2011-03-25 | 2021-07-27 | UNIVERSITé LAVAL | Inhibitors of 17β-HSD1, 17β-HSD3 and 17β-HSD10 |
| SG195118A1 (en) | 2011-06-01 | 2013-12-30 | Estetra S A | Process for the production of estetrol intermediates |
| PT2714712T (pt) | 2011-06-01 | 2016-11-08 | Estetra Sprl | Processo para a produção de intermediários de estetrol |
| EP2383279A1 (en) | 2011-07-19 | 2011-11-02 | Pantarhei Bioscience B.V. | Process for the preparation of estetrol |
| WO2013078413A1 (en) * | 2011-11-22 | 2013-05-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Modulators of lipid storage |
| TW201512215A (zh) | 2013-06-25 | 2015-04-01 | Forendo Pharma Ltd | 治療活性雌三烯噻唑衍生物 |
| JP6456373B2 (ja) * | 2013-06-25 | 2019-01-23 | フォレンド ファーマ リミテッド | １７β−ヒドロキシステロイドデヒドロゲナーゼ タイプ１の阻害剤として治療活性のあるエストラトリエンチアゾール誘導体 |
| JP6556125B2 (ja) * | 2013-06-25 | 2019-08-07 | フォレンド ファーマ リミテッド | １７β−ヒドロキシステロイドデヒドロゲナーゼの阻害剤としての治療的に活性な１７−窒素置換エストラトリエンチアゾール誘導体 |
| JP6545266B2 (ja) | 2014-12-23 | 2019-07-17 | フォレンド ファーマ リミテッド | １７β‐ＨＳＤ１抑制剤のプロドラッグ |
| CN107207561B (zh) * | 2014-12-23 | 2020-03-31 | 佛恩多制药有限公司 | 17β-HSD1–抑制剂的前药 |
| LT3310346T (lt) | 2015-06-18 | 2021-06-10 | Estetra Sprl | Burnoje disperguojama tabletė, turinti estetrolio |
| LT3310345T (lt) | 2015-06-18 | 2021-06-25 | Estetra Sprl | Burnoje disperguojama tabletė, turinti estetrolio |
| DK3701944T3 (da) | 2015-06-18 | 2022-03-14 | Estetra Srl | Oro-dispergerbar doseringsenhed indeholdende en estetrolkomponent |
| CR20180042A (es) | 2015-06-18 | 2018-05-03 | Mithra Pharmaceuticals S A | Unidad de dosificación orodispersable que contiene un componente estetrol. |
| CN105963301B (zh) * | 2016-04-26 | 2018-12-28 | 兰州大学 | 以人fkbp51蛋白为靶点的先导化合物及筛选方法与应用 |
| CZ307437B6 (cs) | 2016-06-07 | 2018-08-22 | Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v.v.i. | 15β-substituované deriváty estronu jako selektivní inhibitory 17β-hydroxysteoiddehydrogenáz |
| KR102712911B1 (ko) | 2016-08-05 | 2024-10-04 | 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 | 월경통 및 생리통의 관리방법 |
| HRP20240679T1 (hr) * | 2017-06-08 | 2024-08-16 | Organon R&D Finland Ltd | 17-oksimi 15.beta.-[3-propanamido]-supstituiranih etera-1,3,5(10)-trien-17-ona za uporabu u inhibiciji 17.beta.-hidroksisteroid dehidrogenaza |
| TWI801561B (zh) | 2018-04-19 | 2023-05-11 | 比利時商依思特拉私人有限責任公司 | 化合物及其用於緩解絕經相關症狀的用途 |
| CN111989105B (zh) | 2018-04-19 | 2024-07-19 | 埃斯特拉私人有限责任公司 | 化合物以及它们在缓解绝经相关症状中的用途 |
| JP7417608B2 (ja) | 2018-12-05 | 2024-01-18 | フォレンド ファーマ リミテッド | １７－ｈｓｄ１阻害剤としての１６（１７）位でピラゾール環と縮合しているエストラ－１，３，５（１０）－トリエン化合物 |
| TWI893101B (zh) | 2020-04-16 | 2025-08-11 | 比利時商埃斯特拉有限責任公司 | 具有降低之副作用之避孕組成物 |
| US20240082208A1 (en) * | 2021-01-08 | 2024-03-14 | Industry-Academic Cooperation Foundation, Yonsei University | Antiviral pharmaceutical composition comprising steroid sulfatase inhibitor |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0367576A2 (en) * | 1988-10-31 | 1990-05-09 | Endorecherche Inc. | Estrogen nucleus derivatives for use in the inhibition of sex steroid activity |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7015211B2 (en) * | 2003-03-21 | 2006-03-21 | Yale University | 15α-substituted estradiol carboxylic acid esters as locally active estrogens |
| GB0306718D0 (en) * | 2003-03-24 | 2003-04-30 | Sterix Ltd | Compound |
| TWI331154B (en) * | 2003-11-12 | 2010-10-01 | Solvay Pharm Gmbh | Novel 17-hydroxysteroid dehydrogenase type i inhibitors |
-
2006
- 2006-05-24 CN CN2006800183025A patent/CN101189251B/zh not_active Expired - Fee Related
- 2006-05-24 CN CN2012103102224A patent/CN102796160A/zh active Pending
- 2006-05-24 BR BRPI0611623-0A patent/BRPI0611623A2/pt not_active IP Right Cessation
- 2006-05-24 ZA ZA200709854A patent/ZA200709854B/xx unknown
- 2006-05-24 UA UAA200714185A patent/UA92348C2/ru unknown
- 2006-05-24 RU RU2007147416/04A patent/RU2412196C2/ru not_active IP Right Cessation
- 2006-05-24 CA CA2609726A patent/CA2609726C/en not_active Expired - Fee Related
- 2006-05-24 KR KR1020077028969A patent/KR101364412B1/ko not_active Expired - Fee Related
- 2006-05-24 AU AU2006251154A patent/AU2006251154B2/en not_active Ceased
- 2006-05-24 EP EP06763273A patent/EP1888615B1/en active Active
- 2006-05-24 MX MX2007014736A patent/MX2007014736A/es active IP Right Grant
- 2006-05-24 ES ES06763273T patent/ES2388297T3/es active Active
- 2006-05-24 WO PCT/EP2006/062587 patent/WO2006125800A1/en not_active Ceased
- 2006-05-24 JP JP2008512837A patent/JP5268635B2/ja not_active Expired - Fee Related
-
2007
- 2007-11-25 IL IL187620A patent/IL187620A/en not_active IP Right Cessation
- 2007-12-21 NO NO20076616A patent/NO20076616L/no not_active Application Discontinuation
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0367576A2 (en) * | 1988-10-31 | 1990-05-09 | Endorecherche Inc. | Estrogen nucleus derivatives for use in the inhibition of sex steroid activity |
Non-Patent Citations (2)
| Title |
|---|
| Donald Poirier et al.D-RING ALKYLAMIDE DERIVATIVES OFESTRADIOL:EFFECT ON ER-BINDING AFFINITYAND ANTIESTROGENIC ACTIVITY.Bioorganic & Medicinal Chemistry Letters6 21.1996,6(21),2537-2542. * |
| Donald Poirier et al.SYNTHESIS OF 17β-ESTRADIOL DERIVATIVES WITH N-BUTYL, N-METHYL ALKYLAMIDE SIDE CHAIN ATPOSITION 15.Tetrahedron47 37.1991,47(37),7751-7766. * |
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0611623A2 (pt) | 2010-09-21 |
| JP5268635B2 (ja) | 2013-08-21 |
| EP1888615B1 (en) | 2012-05-16 |
| ZA200709854B (en) | 2009-03-25 |
| CA2609726A1 (en) | 2006-11-30 |
| RU2007147416A (ru) | 2009-07-10 |
| KR20080012960A (ko) | 2008-02-12 |
| CA2609726C (en) | 2013-10-01 |
| ES2388297T3 (es) | 2012-10-11 |
| AU2006251154A1 (en) | 2006-11-30 |
| IL187620A0 (en) | 2008-03-20 |
| AU2006251154B2 (en) | 2012-06-28 |
| IL187620A (en) | 2014-03-31 |
| MX2007014736A (es) | 2008-02-15 |
| CN102796160A (zh) | 2012-11-28 |
| HK1117538A1 (en) | 2009-01-16 |
| JP2008545678A (ja) | 2008-12-18 |
| CN101189251A (zh) | 2008-05-28 |
| WO2006125800A1 (en) | 2006-11-30 |
| RU2412196C2 (ru) | 2011-02-20 |
| KR101364412B1 (ko) | 2014-02-21 |
| NO20076616L (no) | 2008-02-01 |
| EP1888615A1 (en) | 2008-02-20 |
| UA92348C2 (en) | 2010-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101189251B (zh) | 17β-HSD1和STS抑制剂 | |
| US8435973B2 (en) | 17-beta HSD1 and STS inhibitors | |
| CN101568547B (zh) | 作为17βHSD抑制剂的被取代的雌三烯衍生物 | |
| ES2424395T3 (es) | Derivados de estratrieno y sus usos como inhibidores de la 17-beta-hidroxiesteroide-deshidrogenasa | |
| EP1685150B1 (en) | NOVEL 17beta HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | |
| US8288367B2 (en) | Substituted estratriene derivatives as 17BETA HSD inhibitors | |
| CN1878786B (zh) | 新的I型17β-羟化类固醇脱氢酶抑制剂 | |
| HK1117538B (en) | 17β-HSD1 AND STS INHIBITORS | |
| HK1134298B (en) | Substituted estratrien derivatives as 17beta hsd inhibitors | |
| MXPA06005278A (en) | NOVEL 17beta HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | |
| HK1099309B (en) | Novel 17 hydroxysteroid dehydrogenase type 1 inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1117538 Country of ref document: HK |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1117538 Country of ref document: HK |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120912 Termination date: 20150524 |
|
| EXPY | Termination of patent right or utility model |